Whether pneumonia risk is decreased with anti-TNF therapy is not known; however, patients on anti-TNF therapy do live slightly longer than their untreated counterparts, despite an increased risk in re-activation of chronic infections[67,68]. The gene discussed is TNF; the disease is susceptibility to pneumonia measurement.